Skip to content

Stevanato Group

US · STVN #2012 by market cap Listed 2021
15.65 -0.28 -1.76%
Periodic snapshot; not a real-time feed. · 2026-11-20 16:10

✦ Quant Fair Value how this is computed

Near fair value
11.36 fair value ≈ 19.86 28.36
  • Implied fair-value range of 11.36-28.36, from this stock's own trailing 5-year average P/E applied to trailing EPS.
  • Current price is -21.2% below the average-multiple fair value of 19.86.

Valuation each multiple against its own 5-year range

P/B ratio 2.45 Cheap vs history 20th percentile
5-year average 3.67 · #22 of 51 in Medical Instruments & Supplies
P/E ratio 28.01 Cheap vs history 19th percentile
5-year average 35.53 · forward 24.57 · #13 of 27 in Medical Instruments & Supplies
P/S ratio 3.14 Cheap vs history 16th percentile
5-year average 4.61 · forward 3.04 · #31 of 51 in Medical Instruments & Supplies

Vs. peers Medical Instruments & Supplies

Company Market cap P/E (TTM) P/B Div yield
Stevanato Group (STVN) 4.27B 28.00 2.45 0.39%
Intuitive Surgical (ISRG) 138.33B 48.25 8.65 0.00%
Becton Dickinson & Co (BDX) 57.96B 52.02 2.35 1.97%
Alcon (ALC) 35.92B 54.24 1.64 0.48%
ResMed (RMD) 33.14B 21.46 5.57 1.04%
Medline (MDLN) 32.55B 57.52 2.76 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value16.50 Economic moatNarrow UncertaintyMedium

Trading 5.4% below Morningstar's fair value estimate.

Fair value

Stevanato Group SpA is assigned a 3-star quantitative star rating, indicating our belief that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 4% discount to our quantitative fair value estimate of $16.50 per share; however, some caution is warranted due to this estimate's medium uncertainty rating.

We need more explanatory data to elaborate on this stock's star rating. We strive to explain the factors driving every rating we assign; however, this is not yet possible for a small fraction of our coverage universe.

Economic moat

The company's narrow quantitative moat rating indicates it could outearn its cost of capital and maintain robust margins for 10 years or longer. In addition, the company's moderate financial health score is decent and doesn't seriously concern us with regard to financial distress.

By Quantitative Equity Report

Quote time 2026-11-20 16:10:04 · For reference only, not investment advice and not tailored to your situation.

Stevanato Group discussion 0 comments

Add a comment